# A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis

> **NCT03573323** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1027 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Ixekizumab
- **DRUG:** Guselkumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03573323
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-09
- **Primary completion:** 2019-07-15
- **Final completion:** 2020-01-08
- **Target enrollment:** 1027 (ACTUAL)
- **Last updated:** 2020-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03573323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03573323, "A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03573323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*